Literature DB >> 24429498

Recurrent genetic defects on chromosome 7q in myeloid neoplasms.

N Hosono1, H Makishima2, A Jerez2, K Yoshida3, B Przychodzen2, S McMahon4, Y Shiraishi5, K Chiba5, H Tanaka6, S Miyano7, M Sanada3, I Gómez-Seguí2, A K Verma8, M A McDevitt9, M A Sekeres10, S Ogawa3, J P Maciejewski11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24429498      PMCID： PMC8694066          DOI： 10.1038/leu.2014.25

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation.

Authors:  A Marti; C Wirbelauer; M Scheffner; W Krek
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

2.  Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.

Authors:  H Makishima; A M Jankowska; R V Tiu; H Szpurka; Y Sugimoto; Z Hu; Y Saunthararajah; K Guinta; M A Keddache; P Putnam; M A Sekeres; A R Moliterno; A F List; M A McDevitt; J P Maciejewski
Journal:  Leukemia       Date:  2010-08-19       Impact factor: 11.528

Review 3.  CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases.

Authors:  Laura Hulea; Alain Nepveu
Journal:  Gene       Date:  2012-01-28       Impact factor: 3.688

4.  Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia.

Authors:  Chantal Cadieux; Sylvie Fournier; Alan C Peterson; Christian Bédard; Barry J Bedell; Alain Nepveu
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 5.  Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development.

Authors:  A Nepveu
Journal:  Gene       Date:  2001-05-30       Impact factor: 3.688

6.  Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.

Authors:  L Tamagnone; S Artigiani; H Chen; Z He; G I Ming; H Song; A Chedotal; M L Winberg; C S Goodman; M Poo; M Tessier-Lavigne; P M Comoglio
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

7.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.

Authors:  Thomas Ernst; Andrew J Chase; Joannah Score; Claire E Hidalgo-Curtis; Catherine Bryant; Amy V Jones; Katherine Waghorn; Katerina Zoi; Fiona M Ross; Andreas Reiter; Andreas Hochhaus; Hans G Drexler; Andrew Duncombe; Francisco Cervantes; David Oscier; Jacqueline Boultwood; Francis H Grand; Nicholas C P Cross
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

8.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Saskia M C Langemeijer; Roland P Kuiper; Ruth Knops; Marion Massop; Evelyn R L T M Tönnissen; Adrian van der Heijden; Theresia N Scheele; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

9.  Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Authors:  S N Khan; A M Jankowska; R Mahfouz; A J Dunbar; Y Sugimoto; N Hosono; Z Hu; V Cheriyath; S Vatolin; B Przychodzen; F J Reu; Y Saunthararajah; C O'Keefe; M A Sekeres; A F List; A R Moliterno; M A McDevitt; J P Maciejewski; H Makishima
Journal:  Leukemia       Date:  2013-03-14       Impact factor: 11.528

10.  Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies.

Authors:  H Singh; A A Lane; M Correll; B Przychodzen; D B Sykes; R M Stone; K K Ballen; P C Amrein; J Maciejewski; E C Attar
Journal:  Blood Cancer J       Date:  2013-05-24       Impact factor: 11.037
View more
  21 in total

1.  Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms.

Authors:  Rashmi S Goswami; Sa A Wang; Courtney DiNardo; Zhenya Tang; Yan Li; Wenli Zuo; Shimin Hu; Shaoying Li; L Jeffrey Medeiros; Guilin Tang
Journal:  Mod Pathol       Date:  2016-04-08       Impact factor: 7.842

Review 2.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

Review 3.  Spliceosomal factor mutations and mis-splicing in MDS.

Authors:  Courtney E Hershberger; Noah J Daniels; Richard A Padgett
Journal:  Best Pract Res Clin Haematol       Date:  2020-08-01       Impact factor: 3.020

4.  Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia.

Authors:  Bogdan Dumitriu; Xingmin Feng; Danielle M Townsley; Yasutaka Ueda; Tetsuichi Yoshizato; Rodrigo T Calado; Yanqin Yang; Yoshiyuki Wakabayashi; Sachiko Kajigaya; Seishi Ogawa; Jun Zhu; Neal S Young
Journal:  Blood       Date:  2014-11-18       Impact factor: 22.113

Review 5.  Therapy-related myeloid neoplasms: when genetics and environment collide.

Authors:  Megan E McNerney; Lucy A Godley; Michelle M Le Beau
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

6.  Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells.

Authors:  Xin Zhao; Shouguo Gao; Zhijie Wu; Sachiko Kajigaya; Xingmin Feng; Qingguo Liu; Danielle M Townsley; James Cooper; Jinguo Chen; Keyvan Keyvanfar; Maria Del Pilar Fernandez Ibanez; Xujing Wang; Neal S Young
Journal:  Blood       Date:  2017-10-13       Impact factor: 22.113

7.  Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms.

Authors:  Bianca Tesi; Josef Davidsson; Matthias Voss; Elisa Rahikkala; Tim D Holmes; Samuel C C Chiang; Jonna Komulainen-Ebrahim; Sorina Gorcenco; Alexandra Rundberg Nilsson; Tim Ripperger; Hannaleena Kokkonen; David Bryder; Thoas Fioretos; Jan-Inge Henter; Merja Möttönen; Riitta Niinimäki; Lars Nilsson; Cornelis Jan Pronk; Andreas Puschmann; Hong Qian; Johanna Uusimaa; Jukka Moilanen; Ulf Tedgård; Jörg Cammenga; Yenan T Bryceson
Journal:  Blood       Date:  2017-02-15       Impact factor: 22.113

Review 8.  The significance of CUX1 and chromosome 7 in myeloid malignancies.

Authors:  Matthew R M Jotte; Megan E McNerney
Journal:  Curr Opin Hematol       Date:  2022-03-01       Impact factor: 3.284

9.  Asymmetric aneuploidy in mesenchymal stromal cells detected by in situ karyotyping and fluorescence in situ hybridization: suggestions for reference values for stem cells.

Authors:  Seon Young Kim; Kyongok Im; Si Nae Park; Jiseok Kwon; Jung-Ah Kim; Qute Choi; Sang Mee Hwang; Sung-Hee Han; Sunghoon Kwon; Il-Hoan Oh; Dong Soon Lee
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

10.  Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.

Authors:  Molly K Imgruet; Julian Lutze; Ningfei An; Bonnie Hu; Saira Khan; Jeffrey Kurkewich; Tanner C Martinez; Donald Wolfgeher; Sandeep K Gurbuxani; Stephen J Kron; Megan E McNerney
Journal:  Blood       Date:  2021-09-02       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.